AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38071462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziritaxestat on top of pirfenidone
Number of subjects: 0
Study 38071462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziritaxestat on top of nintedanib
Number of subjects: 0
Study 38071462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziritaxestat alone
Number of subjects: 0
Study 38071462 — intervention group
Group type: EXPERIMENTAL
Intervention: LPA C18:2 reduction
Number of subjects: 0
Study 38071462 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX concentrations
Number of subjects: 0
Study 38071462 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in LPA C18:2
Number of subjects: 0
Study 38071574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 732
Study 38071574 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 732
Study 38071986 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction group (ICS-formoterol dose tapering)
Number of subjects: 208
Study 38071986 — intervention group
Group type: COMPARATOR
Intervention: Reduction group
Number of subjects: 208
Study 38071986 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 208
Study 38071990 — intervention group
Group type: EXPERIMENTAL
Intervention: SIM01 (10 billion colony-forming units in sachets twice daily)
Number of subjects: 463
Study 38071990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 38071994 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Community Adherence Club (TCAC)
Number of subjects: 176
Study 38071994 — intervention group
Group type: COMPARATOR
Intervention: Usual care (passive referral)
Number of subjects: 176
Study 38072156 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAPS intervention (center-based ECCE program)
Number of subjects: 3858
Study 38072158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenously every 3 weeks for ≤93 weeks
Number of subjects: 54
Study 38072158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 54
Study 38072183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (2800 IU/d)
Number of subjects: 700
Study 38072183 — intervention group
Group type: COMPARATOR
Intervention: Standard dose vitamin D3 (400 IU/d)
Number of subjects: 700
Study 38072183 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal preintervention 25(OH)D levels
Number of subjects: 700
Study 38072236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal sleep intervention (SNOO responsive bassinet) plus usual care
Number of subjects: 110
Study 38072236 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 110
Study 38072307 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients undergoing PCI for AMI complicated by CS
Number of subjects: 695
Study 38072307 — intervention group
Group type: EXPERIMENTAL
Intervention: After propensity score matching for female patients undergoing PCI for AMI complicated by CS
Number of subjects: 695
Study 38072326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole + IMRT
Number of subjects: 338
Study 38072326 — intervention group
Group type: COMPARATOR
Intervention: Placebo + IMRT
Number of subjects: 338
Study 38072392 — intervention group
Group type: EXPERIMENTAL
Intervention: Situs Ambiguus (SA)
Number of subjects: 397
Study 38072392 — intervention group
Group type: COMPARATOR
Intervention: Situs Solitus (SS) or Situs Inversus Totalis (SIT)
Number of subjects: 397
Study 38072471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2 max)
Number of subjects: 317
Study 38072471 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular strength (handgrip)
Number of subjects: 317
Study 38072483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1437
Study 38072483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 1437
Study 38072483 — intervention group
Group type: COMPARATOR
Intervention: Propofol (usual care)
Number of subjects: 1437
Study 38072483 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU outcomes
Number of subjects: 1437
Study 38072485 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard handout of nearby dental and aSDoH resources
Number of subjects: 2049
Study 38072485 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographically matched listing of aSDoH resources and a search link for identification of geographically matched dental resources
Number of subjects: 2049
Study 38072485 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographically matched resources along with personalised care navigation
Number of subjects: 2049
Study 38072485 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (control group)
Number of subjects: 2049
Study 38072492 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR-guided PCI
Number of subjects: 1872
Study 38072492 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 1872
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Live births (92%, n=3478)
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriages/abortions (5.5%, n=205)
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stillbirths (2.6%, n=98)
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Home deliveries (22%, n=786)
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (<2500 g)
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm births (gestational age <37 weeks)
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mortality rate
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal mortality rate
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stillbirth rate
Number of subjects: 3731
Study 38072494 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of neonatal deaths
Number of subjects: 3731
Study 38072513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 5 mg/day plus abemaciclib 150 mg b.i.d until disease progression/toxicity
Number of subjects: 29
Study 38072514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 5 mg daily
Number of subjects: 103
Study 38072514 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 500 mg (days 1, 15, and 29, then every 4 weeks)
Number of subjects: 103
Study 38072625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10
Number of subjects: 88
Study 38072743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, Bortezomib, and Dexamethasone (PVd)
Number of subjects: 559
Study 38072743 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and Dexamethasone (Vd)
Number of subjects: 559
Study 38072743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, Bortezomib, and Dexamethasone (PVd) with bortezomib dose adjustment
Number of subjects: 559
Study 38072960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab plus polatuzumab vedotin
Number of subjects: 120
Study 38073038 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily for 14 days
Number of subjects: 0
Study 38073038 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 38073039 — intervention group
Group type: EXPERIMENTAL
Intervention: uEV-MMP-7 in patients with rapid disease progression
Number of subjects: 59
Study 38073039 — intervention group
Group type: COMPARATOR
Intervention: Whole urine MMP-7
Number of subjects: 59
Study 38073039 — intervention group
Group type: COMPARATOR
Intervention: ADPKD tissue MMP-7 expression
Number of subjects: 59
Study 38073180 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth ball application
Number of subjects: 159
Study 38073180 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position
Number of subjects: 159
Study 38073180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 38073386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined visual and auditory gamma-sensory stimulation (40 Hz for six months)
Number of subjects: 38
Study 38073386 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 38
Study 38073465 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral intervention with phone coaching
Number of subjects: 102
Study 38073465 — intervention group
Group type: COMPARATOR
Intervention: Phone monitoring alone
Number of subjects: 102
Study 38073563 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive individuals (systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or use of antihypertensive medications) at 1 year postpartum
Number of subjects: 129
Study 38073563 — intervention group
Group type: COMPARATOR
Intervention: Individuals with normalization of BP at 1 year postpartum
Number of subjects: 129
Study 38073622 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 0
Study 38073622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil, OO)
Number of subjects: 0
Study 38074133 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine Phytosome
Number of subjects: 0
Study 38074133 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38074142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol emulsion
Number of subjects: 0
Study 38074142 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 0
Study 38074293 — intervention group
Group type: EXPERIMENTAL
Intervention: VeriStrat® test (VS)
Number of subjects: 0
Study 38074293 — intervention group
Group type: EXPERIMENTAL
Intervention: MALDI-TOF analysis
Number of subjects: 0
Study 38074293 — intervention group
Group type: EXPERIMENTAL
Intervention: DeepMALDI® analysis
Number of subjects: 0
Study 38074293 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS
Number of subjects: 0
Study 38074312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab treatment
Number of subjects: 0
Study 38074489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for obesity management, combined with sessions with a dietitian and a kinesiologist, for 16 weeks.
Number of subjects: 0
Study 38074489 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving sessions with a dietitian and a kinesiologist, without cognitive behavioral therapy, for 16 weeks.
Number of subjects: 0
Study 38074489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for obesity management.
Number of subjects: 0
Study 38074707 — intervention group
Group type: EXPERIMENTAL
Intervention: PET program (intervention)
Number of subjects: 0
Study 38074707 — intervention group
Group type: COMPARATOR
Intervention: CREAtive writing Training (CREAT) program (active control)
Number of subjects: 0
Study 38074719 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC mixed with tobacco
Number of subjects: 30
Study 38074719 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg THC mixed with tobacco
Number of subjects: 30
Study 38074719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 38075210 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein low glycemic index diet
Number of subjects: 279
Study 38075210 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 279
Study 38075956 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Therapy (HBET) program with behavior change intervention and smartphone app
Number of subjects: 73
Study 38075956 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkingPad app
Number of subjects: 73
Study 38075956 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study 38076348 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (eGFR <30 ml/min/1.73 m²)
Number of subjects: 2663
Study 38076348 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (eGFR ≥30 and <60 ml/min/1.73 m²)
Number of subjects: 2663
Study 38076348 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (eGFR ≥60 ml/min/1.73 m²)
Number of subjects: 2663
Study 38076411 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent HIV infection identified using the Maxim HIV-1 LAg-Avidity EIA assay as part of a recent infection testing algorithm (RITA)
Number of subjects: 6899
Study 38076411 — intervention group
Group type: EXPERIMENTAL
Intervention: Annualized HIV incidence rate
Number of subjects: 6899
Study 38076411 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group comparison for recent HIV infection
Number of subjects: 6899
Study 38076597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cardiac PET/MRI
Number of subjects: 40
Study 38076597 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care Imaging (separate cardiac MRI, PET/CT, and SPECT perfusion imaging)
Number of subjects: 40
Study 38076682 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group (medicated daily for ADHD)
Number of subjects: 60
Study 38076682 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD group
Number of subjects: 60
Study 38076682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after ten soccer headers
Number of subjects: 60
Study 38077080 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART-U intervention (12-week intensive educational sessions and 12-week remotely accessed telephone follow-up)
Number of subjects: 188
Study 38077080 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (eTAU)
Number of subjects: 188
Study 38077080 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART-U intervention
Number of subjects: 188
Study 38077106 — intervention group
Group type: EXPERIMENTAL
Intervention: level D-PPE
Number of subjects: 30
Study 38077106 — intervention group
Group type: EXPERIMENTAL
Intervention: level C-PPE
Number of subjects: 30
Study 38077106 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPR
Number of subjects: 30
Study 38077184 — intervention group
Group type: EXPERIMENTAL
Intervention: Group yoga
Number of subjects: 0
Study 38077184 — intervention group
Group type: COMPARATOR
Intervention: Group low-impact exercise
Number of subjects: 0
Study 38077399 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood IFN-α2 level
Number of subjects: 140
Study 38077399 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing anti-IFN-α2 auto-antibodies
Number of subjects: 140
Study 38077399 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid decline of blood IFN-α2
Number of subjects: 140
Study 38077399 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of plasma SARS-CoV-2 RNA
Number of subjects: 140
Study 38077624 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted trivalent influenza vaccine (aTIV)
Number of subjects: 1779
Study 38077624 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent inactivated influenza vaccine (QIV)
Number of subjects: 1779
Study 38078711 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 1878
Study 38078711 — intervention group
Group type: EXPERIMENTAL
Intervention: Caprini risk score (CRS)
Number of subjects: 1878
Study 38078711 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of tributaries
Number of subjects: 1878
Study 38078711 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of perforating veins
Number of subjects: 1878
Study 38078710 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with micronet-covered plaque-sequestrating stents
Number of subjects: 60
Study 38078710 — intervention group
Group type: COMPARATOR
Intervention: NPP-management (not per-protocol management)
Number of subjects: 60
Study 38078866 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab
Number of subjects: 0
Study 38078870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (10 or 15 mg, once-weekly subcutaneous)
Number of subjects: 670
Study 38078870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study 38078870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 670
Study 38078898 — intervention group
Group type: EXPERIMENTAL
Intervention: Camonsertib monotherapy
Number of subjects: 60
Study 38079084 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-HPG nanoemulsion lubricant eye drops, self-administered one drop four times daily for 28 ± 2 days
Number of subjects: 119
Study 38079089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily orally until disease progression or unacceptable toxicity
Number of subjects: 17
Study 38079095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg oral daily
Number of subjects: 32
Study 38079095 — intervention group
Group type: COMPARATOR
Intervention: Probe drug alone
Number of subjects: 32
Study 38079201 — intervention group
Group type: EXPERIMENTAL
Intervention: ChatV health bot
Number of subjects: 40
Study 38079324 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity during sport and leisure time (MVPA-SL) measured at diagnosis (T0) and 6, 12, 24, and 60 months (T6 to T60) postdiagnosis using the SQUASH questionnaire.
Number of subjects: 4900
Study 38079324 — intervention group
Group type: COMPARATOR
Intervention: Comparison with an age- and sex-matched sample of the general Dutch population.
Number of subjects: 4900
Study 38079634 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 360
Study 38079634 — intervention group
Group type: COMPARATOR
Intervention: Piecemeal endoscopic mucosal resection (EMR)
Number of subjects: 360
Study 38081155 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 1822
Study 38081155 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 1822
Study 38081155 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib (both dosages)
Number of subjects: 1822
Study 38081155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1822
Study 38081463 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive SIJ fusion with triangular titanium implants (TTI)
Number of subjects: 0
Study 38081463 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management (NSM)
Number of subjects: 0
Study 38081585 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (15% energy, 30-60 g/d; 2.6-5.2 g C18:3n-3/d)
Number of subjects: 115
Study 38081585 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 115
Study 38081585 — intervention group
Group type: COMPARATOR
Intervention: Control diet (abstention from walnuts)
Number of subjects: 115
Study 38081671 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) tools in healthcare
Number of subjects: 13
Study 38081955 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis (PrEP) for HIV prevention
Number of subjects: 22
Study 38081955 — intervention group
Group type: COMPARATOR
Intervention: Low adherence group
Number of subjects: 22
Study 38081955 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence group
Number of subjects: 22
Study 38082096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 101
Study 38082227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg/kg dexmedetomidine
Number of subjects: 60
Study 38082227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 60
Study 38082227 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 60
Study 38082231 — intervention group
Group type: EXPERIMENTAL
Intervention: FPSS (flavored PEG and sulfate solution)
Number of subjects: 60
Study 38082231 — intervention group
Group type: COMPARATOR
Intervention: PEG-SD (PEG and sports drink)
Number of subjects: 60
Study 38082231 — intervention group
Group type: EXPERIMENTAL
Intervention: FPSS
Number of subjects: 60
Study 38082231 — intervention group
Group type: COMPARATOR
Intervention: PEG-SD
Number of subjects: 60
Study 38082248 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor walk group (OWG) - met 2x/week for 10 weeks
Number of subjects: 190
Study 38082248 — intervention group
Group type: COMPARATOR
Intervention: Weekly reminders (WR) group - received phone reminders 1x/week for 10 weeks
Number of subjects: 190
Study 38082248 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor walk group (OWG)
Number of subjects: 190
Study 38082255 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable-based gait assessments using three inertial sensors (LEGSys™, BioSensics LLC) during Timed Up and Go, 5 × sit-to-stand, and 2-min walk tests.
Number of subjects: 23
Study 38082273 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 785
Study 38082293 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care practices implementation
Number of subjects: 10
Study 38082293 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic Learning Sessions
Number of subjects: 10
Study 38082293 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching visits by an expert
Number of subjects: 10
Study 38082293 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexive monitoring
Number of subjects: 10
Study 38082337 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS) strategy involving PSA assessment, DRE, and periodic prostate biopsies every 6 months, multiparametric MRI every two years, and prostate biopsy at month 12 and then every two years.
Number of subjects: 200
Study 38082337 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS) strategy
Number of subjects: 200
Study 38082350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 90
Study 38082350 — intervention group
Group type: COMPARATOR
Intervention: Health promotion program
Number of subjects: 90